

UNCLASSIFIED

AD NUMBER
ADB200784
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Govt agencies only; Proprietary Info.; 30 Jun 95. Other requests shall be referred to U.S. Army Medical Research and Material Command, Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr., 21 Apr 97

THIS PAGE IS UNCLASSIFIED

AD _____

CONTRACT NO: DAMD 17-92-C-2081


TITLE: SYNTHESIS OF ANTIDOTES AND PROPHYLACTICS FOR ORGANOPHOSPHORUS
ACETYLCHOLINESTERASE INHIBITORS

PRINCIPAL INVESTIGATOR: Richard J. Sundberg

CONTRACTING ORGANIZATION: University of Virginia
Department of Chemistry
Mc Cormick Road
Charlottesville, VA 22901

REPORT DATE: 30 June 1995

TYPE OF REPORT: Annual



PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only; ~~report contains~~ proprietary information; other requests for this document shall be referred to the U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland 21702-5012

Attn: MCMR-RMI-S

30 June 95

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19950718 008

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE

Form Approved
DMS No. 0704-0188

Instructions: This report is to be filled out by the person or persons who prepared the report, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 30 June 1995		3. REPORT TYPE AND DATES COVERED Annual 6-1-94 to 6-30-95	
4. TITLE AND SUBTITLE Synthesis of Antidotes and Prophylactics for Organophosphorus Acetylcholinesterase Inhibitors				5. FUNDING NUMBERS DAMD 17-92-C-2081	
6. AUTHOR(S) Richard J. Sundberg-Principal Investigator					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Virginia Department of Chemistry McCormick Road Charlottesville, VA 22901				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION/AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only; report contains proprietary information; other requests for this document shall be referred to the U.S. Army Medical Research and Materiel Command, ATTN: MCMR-RMI-S, Fort Detrick, Frederick 21702-5012.				12b. DISTRIBUTION CODE 30 June 95	
13. ABSTRACT (Maximum 200 words) Work has been completed on 4-substituted and 6-substituted N,N-Dimethylcarbamoyloxy derivatives in the imidazo[1,2-a]pyridinium series (six new compounds). Previously four 8-substituted compounds had been prepared. Work has been begun on the 7-substituted series. In each series the goal is to prepare the parent compound and three 2-substituted analogs containing methyl, isopropyl and phenyl substituents. <u>In vitro</u> biological assays have been performed on all available derivatives (eleven compounds). The 4- and 8-substituted analogs are more active than the 6-substituted compounds.					
14. SUBJECT TERMS Prophylactic, antidote, organophosphorus, acetylcholinesterase inhibitors, carbamates imidazo[1,2-a]pyridines				15. NUMBER OF PAGES 22	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT unclassified		18. SECURITY CLASSIFICATION OF THIS PAGE unclassified		19. SECURITY CLASSIFICATION OF ABSTRACT unclassified	
				20. LIMITATION OF ABSTRACT limited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

na Where copyrighted material is quoted, permission has been obtained to use such material.

na Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

✓ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

na In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

na For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

na In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

na In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

na In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Accession For	
NTIS GRA&I	☐
DTIC TAB	☒
Unannounced	☐
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
B-3	

Richard M. [Signature] 6 June 95
PI - Signature Date

Table of Contents


I. Introduction.....	1
II. Summary of Staffing.....	2
III. New Compounds Prepared.....	2
IV. Synthetic Methods.....	4
V. Biological Activity.....	6
VI. Future Plans.....	8
VII. Experimental Section.....	9
VIII. References.....	18

I. Introduction

The development of prophylactic and therapeutic agents to prevent the lethal and incapacitating effects of organophosphorus (OP) acetylcholinesterase (AChE) inhibitors has remained a concern despite the development of international protocols to prohibit their military use. (1) As this year's events in Tokyo demonstrate, the preparation and delivery of the OP is within the capacity not only of non-complying governments, but also non-governmental entities. (2)

From a broader scientific perspective, additional understanding of the function of AChE and its therapeutic adjustment is important because of the crucial role of AChE in the function of the nervous system. Treatment of myasthenia gravis is accomplished by partial inhibition of AChE. (3) Furthermore, the postulate that some of the effects of Alzheimer's disease are due to a deficit in acetylcholine-mediated functions has led to interest in AChE inhibitors in therapy of Alzheimer's disease. (4)

Our studies began with the recognition that certain heteroaromatic quaternary salts, derivatives of imidazo[1,2-a]pyridines in particular showed prophylactic activity towards soman. (5) In the preceding annual report we described the preparation of several 8-substituted and 4-substituted derivatives. (6) During the first quarter of the current year the 4-substituted series (3 additional compounds) and the 6-substituted (3 additional compounds) were completed. This leaves only the 7-substituted compounds unrepresented. In each series a range of 2-substituents was prepared, usually including the parent, methyl, isopropyl and phenyl derivatives.




Synthesis of new compounds was temporarily discontinued in September, 1994 when the research associate resigned, but have now been resumed as will be described. Additional biological evaluation was continued during the September-November quarter providing preliminary in vitro data for all newly synthesized compounds. These results are discussed in Section V.

II. Summary of Staffing


	<u>Period</u>	<u>Effort %</u>	<u>Pay %</u>
Richard J. Sundberg	1-June 94-31 Aug 94	33	33
	1-Sep 94-31 May 95	5	0
	1-June 95-30 June 95	33	33
Phouc Van Nguyen	1-June 94-31 Aug 94	100	100
Songjun Jiang	22-May 95-30 June 95	100	100
Janine Glavovic	1-June 94-25 Jan 95	100	100
(unpaid leave 20 Jan 95-28 Feb 95)			

III. New Compounds Prepared

Six new compounds were prepared for submission during the year. The samples represent the completion of the 5- and 6-carbamates series. In both series the parent 1-methyl quaternary salts and the 2-methyl, 2-isopropyl and 2-phenyl were prepared. The 2-phenyl analog (BM 08648) of the 6-carbamates series was submitted earlier (Contract number: DAMD-17-89-C-9014).









	R	X	
1	H	TsO	PN-III-268
2	Me	TsO	PN-IV-33
3	i-Pr	I	PN-III-240



	R	X	
4	H	Cl	PN-III-220
5	i-Pr	I	PN-IV-36
6	Ph	I	PN-III-236

The compounds are listed in Table 1 and details of the preparation are given in the Experimental Section.


Table I. New Compounds Submitted

Our sample Number	WRAIR Bottle Number	WR Number	Date of Submission	Structure
PN-III-220	BN38865		8-7-94	
PN-III-236	BN38874		8-7-94	
PN-III-240	BN38883		8-7-94	
PN-III-268	BN40481	WR279951	15-9-94	
PN-IV-33	BN40507	WR279953	15-9-94	
PN-IV-36	BN40490	WR279952	15-9-94	

IV. Synthetic Methods


The synthetic routes for the compounds are outlined in Scheme 1, 2 and 3.

Scheme 1




a) ClCH_2CHO or $\text{ClCH}_2\text{COCH}_3$. b) $(\text{CH}_3)_2\text{CHCOCH}_2\text{Br}$. c) MeONa ; Me_2NCOCl , $\text{C}_5\text{H}_5\text{N}$.
d) NaOH . e) Me_2NCOCl , $\text{C}_5\text{H}_5\text{N}$, Δ . f) MeOTs or MeI .

Scheme 2



a) ClCH_2CHO . b) PhCOCH_2Br , Δ . c) 70% H_2SO_4 , Δ . d) NaNH_2 , MeI . e) NaH , DMF . f) ClCONMe_2 . g) MeI , THF .


Scheme 3



a) NaH ; $\text{Me}_2\text{CHCOCH}_2\text{Br}$. b) NaH ; Me_2NCOCl . c) MeI

This methodology largely parallels that developed earlier for the 6- and 8-substituted series. However the 5-substituted series presented some special problems which appear to be associated with the existence of the compounds, at least under certain conditions in the oxo tautomeric structure **4a**. This required the use of a strong base to effect both the N-alkylation (step d, Scheme 2) and carbamoylation (step f, Scheme 2; step b, Scheme 3).

The 7-substituted series is now under investigation. There are surprisingly few entries to the 4-oxypyridin-2-amines needed as starting materials. The existing route to 4-hydroxypyridine-2-amine begins with picolinic acid.⁽⁷⁾



This route appeared sufficiently cumbersome to encourage exploration of novel routes but preliminary efforts by Dr. Nguyen were not encouraging. As a result, Dr. Jiang has begun examining this route in the hopes of improving it. The initial results are very encouraging. Since it is difficult to conceive of an electrophilic or radical substitution mechanism which would result in the observed regioselectivity, we hypothesized that a combination of nucleophilic addition and oxidation was involved. Following this hypothesis the effect of added bromide and iodide as potential nucleophilic catalysts was examined. Both had substantial accelerating effects and in the presence of KI the reaction is complete in 3-4h. Preliminary runs have been done on each of the other steps and it appears they will be satisfactory for the preparation of the required 4-hydroxy-2-aminopyridine.

V. Biological Activity

While no direct evidence on the point is available it is reasonable to assume that the mechanism of action of the imidazo[1,2-a]pyridinium carbomates is analogous to that of pyridostigmine. That is, it is anticipated that they act as reversible AChE inactivators by carbamoylation of the active site serine. The positive charges present in both


pyridostigmine and the imidazo[1,2-a]pyridinium salts are also presumably important in mimicking the charge of the natural substrate acetylcholine. If these presumptions are correct, measurement of AChE inhibition should be a predictive test of prophylactic activity. We therefore carry out an in vitro AChE inhibition assay following the method of Ellman using electric eel AChE.⁽⁸⁾ Results from the 5-, 6- and 8-substituted imidazo[1,2-a]pyridinium salts are given in Table 2.

Table 2. Activity as Acetylcholinesterase Inhibitors.

Our Sample	WRBN	IC ₅₀	R	Carbamoyloxy Substitution
PN-III-220	BN38865	0.04±0.01	H	5
PN-III-194	BN38856	0.03±0.01	CH ₃	5
PN-IV-36	BN40490	0.014±0.005	CH(CH ₃) ₂	5
PN-III-236	BN38874	0.09±0.01	Ph	5
PN-III-268	BN40481	15.2±2.5	H	6
PN-IV-33	BN40507	31.4±12.4	CH ₃	6
PN-III-240	BN3883	16.0±2.0	CH(CH ₃) ₂	6
PN-II-278	BN36049	0.04±0.005	H	8
PN-II-222	BN34830	0.075±0.005	CH ₃	8
PN-III-28	BN36058	1.8±0.2	CH(CH ₃) ₂	8
PN-II-258	BN36030	2.5±0.3	Ph	8

From these results it appears that the 5- and 8-substituted compounds are substantially more active than the 6-substituted compounds. Under these conditions pyridostigmine has a IC₅₀ of 0.7μM. The apparent sensitivity to position of substitution might be the result of several factors. It may originate in a preferred orientation in the binding site. There may also be an inherent reactivity factor which should correlate with the leaving group ability of the heterocycle. In this respect the 5- but not the 6- or 8- isomers benefit from additional resonance stabilization. The 7-substituted system also has this stabilization available. If time permits upon completion of the synthesis and in vitro

bioassay we plan to explore these issues by modelling the fit of the compounds in the AChE active site.



To date no in vivo biological results have been provided for this series of compounds.

VI. Future Plans

Assuming the described experimental procedure will provide a basis for preparation of the 6-carbamoyloxy series of compounds, during the forthcoming months we will prepare as many of the compounds in the series as possible. Initial emphasis will be on the N,N-dimethylcarbamates with $R^2 = H, CH_3, CH(CH_3)_2$ and phenyl. When these are completed we will direct our attention to the N-methyl series. As the compounds become available, the in vitro acetylcholinesterase inhibition assays will be done. Experimental work is scheduled to terminate on December 31, 1995. During January, 1996, we will prepare the final report and during February - April we will prepare the results for publication and await the review of the final report. We expect to have completed the project by no later than May 31, 1996.

VII. Experimental Section

6-Benzoyloxyimidazo[1,2-a]pyridine (1a)

A mixture of 2-amino-5-benzoyloxypyridine⁹ (6.52 g, 30.4 mmol) and chloroacetaldehyde (6.37 g, 36.5 mmol, 45% w/w in water) in acetone (150 mL) was gently refluxed. The reaction mixture was evaporated to dryness under aspirator pressure. The resulting residue was neutralized with satd NaHCO₃ solution and extracted with CHCl₃ (4 x 100 mL). The organic layers were washed with brine (2 x 100 mL), dried (anhyd Na₂SO₄), filtered and evaporated to dryness. Purification of the crude by column chromatography (silica gel, 20% of hexane in EtOAc) gave **1a** (3.34 g, 46 %) as a tan solid from EtOAc/hexane: mp 144-145 °C; R_f = 0.25 (EtOAc-hexane, 5:1); ¹H NMR (CDCl₃) δ 8.28 (d, 1 H, J = 2.1 Hz), 8.19-8.22 (m, 2 H), 7.51-7.70 (m, 6 H), 7.12 (dd, 1 H, J = 2.1, 9.6 Hz); ¹³C NMR (CDCl₃) δ 164.87, 154.77, 143.76, 139.69, 134.63, 134.02, 130.20, 128.69, 121.13, 118.54, 117.80, 113.40. Anal. Calcd for C₁₄H₁₀N₂O₂: C, 70.58; H, 4.23; N, 11.76. Found: C, 70.47; H, 4.22; N, 11.75.

2-Methyl-6-benzoyloxyimidazo[1,2-a]pyridine (2a)

A mixture of 2-amino-5-benzoyloxypyridine (1.79 g, 8.36 mmol) and chloroacetone (0.77 mL, 9.2 mmol) in absolute ethanol (35 mL) was refluxed for 10 h. Two more portions of chloroacetone were added (0.3 mL each) over a period of 10 h. The solvent was then removed under reduced pressure. The resulting residue was treated with a satd NaHCO₃ solution. The aqueous mixture was extracted with CHCl₃ (4 x 25 mL) and dried (anhyd Na₂SO₄). Removal of solvent to dryness gave crude product, which was purified by column chromatography (silica gel, EtOAc-hexane, 2:1) to give **2a** (0.88 g, 41.8%) as off-white needles from EtOAc/hexane: mp 178-180 °C; R_f = 0.25 (EtOAc-hexane, 2:1); ¹H NMR (CDCl₃) δ 8.20 (ca, 1 H), 8.15-8.17 (m, 2 H), 7.62-7.68 (m, 1 H), 7.49-7.54 (m, 3 H), 7.34 (d, 1 H, J = 0.3 Hz), 7.05 (dd, 1 H, J = 2.1, 9.6 Hz), 2.46 (s, 3 H); ¹³C NMR (CDCl₃) δ 164.87, 144.47, 143.26, 139.21, 133.88, 130.10, 128.60, 120.42, 117.95, 116.55, 110.51, 14.33. Anal. Calcd for C₁₅H₁₂N₂O₂: C, 71.42; H, 4.79; N, 11.10. Found: C, 71.25; H, 4.91; N, 11.22.

2-(2-Propyl)imidazo[1,2-a]pyridin-6-ol (3a)

A mixture of 2-amino-5-benzoyloxypyridine (0.89 g, 4.2 mmol) and 1-bromo-3-methylbutan-2-one¹⁰ (0.75g, 4.6 mmol) in dry THF (15 mL) was refluxed for 16 h. Solvent was removed to dryness and the resulting residue was treated with aq 20% KOH solution. The mixture was stirred at 100 °C (oil bath temperature) for 1 h, then cooled and neutralized with concd HCl solution to give solid **3a** (0.52 g, 71 %): $R_f = 0.43$ (CHCl₃-MeOH, 9:1); ¹H NMR (CDCl₃) δ 7.76 (d, 1 H, $J = 1.8$ Hz), 7.19 (overlapped d, 1 H, $J = 9.6$ Hz), 7.18 (overlapped s, 1 H), 7.02 (dd, 1 H, $J = 1.8, 9.6$ Hz), 3.08 (septet, 1 H, $J = 7.1$ Hz), 1.32 (d, 6 H, $J = 7.1$ Hz); ¹³C NMR (CDCl₃) δ 151.97, 147.48, 140.81, 121.46, 115.01, 110.72, 107.87, 27.92, 22.46.

Imidazo[1,2-a]pyridin-5-ol (**4a**)

A mixture of 2,6-diaminopyridine (10.9 g, 0.1 mol) and chloroacetaldehyde (17.5 g, 45% w/w in water, 0.1 mol) in acetone (200 mL) was refluxed overnight. The reaction mixture was cooled and filtered to give a solid, which was washed with several portions of fresh acetone and dried under vacuum to afford 5-aminoimidazo[1,2-a]pyridine hydrochloride (16.9 g, 100%) as tan solid: ¹H NMR (DMSO-d₆) δ 8.45 (d, 1 H, $J = 2.4$ Hz), 8.08 (d, 1 H, $J = 2.4$ Hz), 7.99 (br s, 2 H), 7.69 (dd, 1 H, $J = 7.8, 8.4$ Hz), 7.00 (d, 1 H, $J = 8.4$ Hz), 6.49 (d, 1 H, $J = 7.8$ Hz).

A mixture of 5-aminoimidazo[1,2-a]pyridine hydrochloride (16.6 g, 97.8 mmol) in 70% H₂SO₄ solution was stirred at 120 °C (oil bath temperature) for 10 h. The reaction mixture was cooled and carefully neutralized with an aq 20% NaOH solution. Filtration of the mixture gave **4a** (10.93 g, 75.4%) as an olive green solid: $R_f = 0.53$ (CHCl₃-MeOH, 9:1); ¹H NMR (DMSO-d₆) δ 7.64 (d, 1 H, $J = 2.1$ Hz), 7.53 (d, 1 H, $J = 2.1$ Hz), 7.34 (dd, 1 H, $J = 8.1, 8.4$ Hz), 6.15 (d, 1 H, $J = 8.1$ Hz), 5.63 (d, 1 H, $J = 8.4$ Hz), 1.82 (br s, 1 H).

2-(2-Propyl)imidazo[1,2-a]pyridin-5-ol (**5a**)

To a cooled mixture of sodium hydride (1.46 g, 61.0 mmol, washed with pentane twice) in dry DMF (30 mL) was added slowly a solution of 1-amino-6-hydroxypyridine¹¹ (4.77 g, 40 mmol) in dry DMF (30 mL). The mixture was stirred in the cooling bath for 15 min., then warmed and stirred at room temperature for 3 h. A solution of 1-bromo-3-methylbutan-2-one (7.26 g, 44 mmol) in dry THF (20 mL) was added at once. The reaction mixture was stirred at 80 °C (oil bath temperature) overnight. Solvent was removed to dryness under reduced pressure. The resulting residue was partitioned between water and CHCl₃. The aqueous phase was extracted with CHCl₃ (4 x 40 mL). The organic layers were washed with water, brine and dried (anhyd Na₂SO₄). Removal of solvent gave a crude product, which was purified by column chromatography (silica gel, CHCl₃-MeOH, 9:1) to give **5a** (3.32 g, 47.1%) as a tan solid: mp 163-165 °C; *R*_f = 0.5 (CHCl₃-MeOH, 9:1); ¹H NMR (CDCl₃) δ 7.51 (s, 1 H), 7.37 (t, 1 H, *J* = 8.4 Hz), 6.41 (d, 1 H, *J* = 8.4 Hz), 5.98 (d, 1 H, *J* = 8.4 Hz), 3.13 (septet, 1 H, *J* = 6.9 Hz), 1.39 (d, 6 H, *J* = 6.9 Hz); ¹³C NMR (CDCl₃) δ 156.84, 142.73, 139.94, 136.05, 103.39, 97.32, 89.31, 25.90, 21.62. Anal. Calcd for C₁₀H₁₂N₂O: C, 68.16; H, 6.86; N, 15.90. Found: C, 67.87; H, 6.88; N, 15.65.

2-Phenylimidazo[1,2-a]pyridin-5-ol (**6a**)

A solution of 2-bromoacetophenone (19.9 g, 0.1 mol) in dry THF (60 mL) was added dropwise to a mixture of 2,6-diaminopyridine (10.9 g, 0.1 mol) in THF (80 mL) at reflux temperature. The mixture was stirred at reflux overnight. 2,6-Diaminopyridine (3g) was added to the mixture which was refluxed for a further 5 h. The solvent was evaporated to dryness and the resulting residue was washed with Et₂O (3 x 100 mL) and then dissolved in methanol (150 mL). Conc'd HBr solution (3 mL) was added and the mixture was stirred at reflux for 30 min. Solvent was evaporated to dryness. The residue was neutralized with sat'd NaHCO₃ solution and the mixture was extracted with CHCl₃ (4 x 100 mL). The organic layers were washed with brine, dried (anhyd Na₂SO₄) and filtered via a column of silica gel, eluted with a mixture of 20% hexane in ethyl acetate to give 5-amino-2-phenylimidazo[1,2-a]pyridine (5.27 g, 25.2%): *R*_f = 0.44 (EtOAc-hexane, 4:1); ¹H NMR (CDCl₃) δ 7.94, (dd, 2 H, *J* = 1.4, 8.4 Hz), 7.64 (s, 1 H), 7.37-7.43 (m, 2 H), 7.29-7.34 (m, 1 H), 7.17 (d, 1 H, *J* = 8.8 Hz), 7.09 (dd, 1 H, *J* = 7.2, 8.8 Hz), 6.04 (dd, 1 H, *J* = 1.1, 7.2 Hz), 4.45 (br s, 2 H).

The treatment of 5-amino-2-phenylimidazo[1,2-a]pyridine (2.83 g, 13.5 mmol) with an aqueous 70% H₂SO₄ solution as described for **4a** gave **6a** (2.62 g, 92.2 %) as an olive green solid: R_f = 0.68 (CHCl₃-MeOH, 9:1); ¹H NMR (DMSO-d₆) δ 8.24 (s, 1 H), 7.89 (d, 2 H, J = 7.8 Hz), 7.35-7.50 (m, 5 H), 6.24 (d, 1 H, J = 8.1 Hz), 5.72 (d, 1 H, J = 8.4 Hz).

6-(N,N-Dimethylcarbamoyloxy)imidazo[1,2-a]pyridine (1b)

A mixture of **1a** (1.80 g, 7.6 mmol) and sodium methoxide (0.61 g, 11.3 mmol) in dry pyridine (50 mL) was stirred at 75 °C overnight. N,N-Dimethylcarbamoyl chloride (1.18 mL, 12.8 mmol) was added slowly via syringe. The reaction mixture was stirred for 10 h. Solvent was removed to dryness and the resulting residue was partitioned between a satd solution of NaHCO₃ and CHCl₃. The aqueous phase was extracted with CHCl₃ (4 x 30 mL). The organic layers were washed with brine, dried (anhyd Na₂SO₄) and filtered. Removal of solvent to dryness gave the crude product which was purified by column chromatography (silica gel, CHCl₃-MeOH, 50:1) to give **1b** (1.37g, 88.8%) as a pale yellow solid from EtOAc/hexane: mp 123-123.5 °C; R_f = 0.23 (CHCl₃-MeOH, 50:1); ¹H NMR (CDCl₃) δ 8.13 (ca, 1 H), 7.63 (d, 1 H, J = 1.2 Hz), 7.57 (d, 1 H, J = 9.6 Hz), 7.55 (s, 1 H), 7.03 (dd, 1 H, J = 2.1, 9.6 Hz), 3.11 (s, 3 H), 3.03 (s, 3 H); ¹³C NMR (CDCl₃) δ 143.67, 140.21, 134.36, 121.70, 118.48, 117.39, 113.19, 36.86, 36.47. Anal. Calcd for C₁₀H₁₁N₃O₂: C, 58.53; H, 5.40; N, 20.48. Found: C, 58.67; H, 5.52; N, 20.54.

2-Methyl-6-(N,N-dimethylcarbamoyloxy)imidazo[1,2-a]pyridine (2b)

The reaction of **2a** (3.3 g, 13.1 mmol) with sodium methoxide (1.06 g, 19.6 mmol) and N,N-dimethylcarbamoyl chloride (2.4 mL, 26.2 mmol) in dry pyridine (25 mL) at 95 °C (oil bath temperature) as described for **1b** gave **2b** (0.89 g, 31%) after purification by column chromatography (silica gel, gradient elution, 2-14% of ethanol in EtOAc). Decolorization of **2b** with charcoal in MeOH followed by recrystallization in EtOAc/hexane gave pale yellow needles: mp 133-134 °C; R_f = 0.40 (EtOAc-EtOH, 9:1); ¹H NMR (CDCl₃) δ 8.02 (d, 1 H, J = 2.1 Hz), 7.44 (d, 1 H, J = 9.6 Hz), 7.30 (s, 1 H), 6.97 (dd, 1 H, J = 2.1, 9.6 Hz), 3.10 (s, 3 H), 3.02 (s, 3 H), 2.44 (s, 3 H); ¹³C NMR (CDCl₃) δ 154.40, 144.20, 143.22, 139.78, 121.04, 117.98, 116.22, 110.34, 36.80, 36.42,

14.37. Anal. Calcd for $C_{11}H_{13}N_3O_2$: C, 60.26; H, 5.98; N, 19.17. Found: C, 60.33; H, 6.02; N, 19.15.

2-(2-Propyl)-6-(N,N-dimethylcarbamoyloxy)imidazo[1,2-a]pyridine (3b)

A mixture of **3a** (0.21 g, 1.2 mmol) and N,N-dimethylcarbamoyl chloride (0.19 g, 1.8 mmol) in dry pyridine (10 mL) was stirred at 80 °C overnight. Solvent was then evaporated to dryness under reduced pressure and the resulting residue was partitioned between a satd $NaHCO_3$ solution and $CHCl_3$. The aqueous phase was extracted with $CHCl_3$ (6 x 20 mL). The organic layers were washed with brine (2 x 20 mL), dried (anhyd Na_2SO_4), filtered and evaporated to dryness. Purification of the crude by column chromatography (silica gel; EtOAc-hexane, 4:1) afforded **3b** (0.21 g, 70%) as a thick oil: R_f = 0.29 (EtOAc-hexane, 4:1); 1H NMR ($CDCl_3$) δ 7.95 (d, 1 H, J = 2.2 Hz), 7.39 (d, 1 H, J = 9.9 Hz), 7.20 (s, 1 H), 6.87 (dd, 1 H, J = 2.2, 9.9 Hz), 2.92-3.07 (overlapped m, 4 H), 2.91 (s, 3 H), 1.26 (d, 6 H, J = 6.9 Hz); ^{13}C NMR ($CDCl_3$) δ 154.75, 154.20, 142.90, 139.51, 120.89, 118.06, 116.19, 108.15, 36.50, 36.19, 28.21, 22.20.

1-Methylimidazo[1,2-a]pyridin-5-one (4b)

A mixture of **4a** (2.68 g, 20 mmol) and sodium amide (1.09 g, 28 mmol) in dry DMF (30 mL) was stirred at room temperature for 30 min. Methyl iodide (1.62 mL, 26 mmol) was added dropwise by syringe and the mixture was stirred at room temperature for 2 h. Solvent was evaporated to dryness under vacuum and the resulting residue was partitioned between a satd $NaHCO_3$ solution and $CHCl_3$. Insoluble material was removed by filtration. The aqueous phase was extracted with $CHCl_3$ (5 x 50 mL). The organic layers were washed with brine (2 x 50 mL), dried (anhyd Na_2SO_4) and filtered. Removal of solvent yielded a crude product which was purified by column chromatography (silica gel, 5% of MeOH in $CHCl_3$) to afford **4b** (1.44 g, 48.6 %) as an off-white solid from acetone/hexane: mp 70-72 °C; R_f = 0.38 ($CHCl_3$ -MeOH, 19:1); 1H NMR ($CDCl_3$) δ 7.74 (d, 1 H, J = 2.4 Hz), 7.44 (t, 1 H, J = 8.4 Hz), 6.97 (d, 1 H, J = 2.4 Hz), 6.01 (d, 2 H, J = 8.4 Hz), 3.68 (s, 3 H); ^{13}C NMR ($CDCl_3$) δ 156.97, 142.44, 136.98, 120.24, 108.46, 99.41, 83.47, 32.85.

2-(2-Propyl)-5-(N,N-dimethylcarbamoyloxy)imidazo[1,2-a]pyridine (5b)

To an ice-cooled mixture of sodium hydride (0.5 g, 20.8 mmol, washed with pentane twice and dried under Ar) in dry THF (20 mL) was added via canula a solution of **5a** (2.64 g, 15 mmol) in dry THF (15 mL). The mixture was warmed up and stirred at 50 °C for 3 h. N,N-Dimethylcarbamoyl chloride (2.07 mL, 22.5 mmol) was then added by syringe. After being stirred at 50 °C for 5 h, the reaction mixture was evaporated to dryness and the resulting residue was partitioned between water and CHCl₃. The aqueous phase was extracted with CHCl₃ (4 x 30 mL). The organic layers were washed with brine (2 x 30 mL), dried (anhyd Na₂SO₄) and filtered. Evaporation of the solvent gave crude product which was purified by column chromatography (silica gel, 20% of hexane in EtOAc) to give **5b** (2.83 g, 76.3 %) as colorless needles from EtOAc/hexane: mp 91-92 °C; R_f = 0.5 (EtOAc-hexane, 9:1); ¹H NMR (CDCl₃) δ 7.42 (dd, 1 H, J = 0.6, 9.0 Hz), 7.24 (s, 1 H), 7.17 (dd, 1 H, J = 7.5, 9.0 Hz), 6.58 (dd, 1 H, J = 0.6, 7.5 Hz), 3.23 (s, 3 H), 3.07-3.16 (overlapped m, 1 H), 3.08 (overlapped s, 3 H), 1.38 (d, 6 H, J = 6.9 Hz); ¹³C NMR (CDCl₃) δ 154.21, 151.81, 146.57, 140.48, 124.34, 113.36, 102.77, 101.28, 37.09, 36.72, 28.47, 22.41. Anal. Calcd for C₁₃H₁₇N₃O₂: C, 63.14; H, 6.93; N, 16.99. Found: C, 63.24; H, 6.97; N, 16.92.

2-Phenyl-5-(N,N-dimethylcarbamoyloxy)imidazo[1,2-a]pyridine (**6b**)

Carbamoylation of **6a** (2.6 g, 12.3 mmol) with sodium hydride (0.2 g, 8.6 mmol) and N,N-dimethylcarbamoyl chloride (0.79 mL, 8.6 mmol) in dry DMF (25 mL) as described earlier for **5b** afforded a crude product which was purified by column chromatography (silica gel; 2% of MeOH in CHCl₃) to give **6b** (0.67 g, 42 %) as a yellow solid from EtOAc/hexane: mp 152-153 °C; R_f = 0.57 (CHCl₃-MeOH, 24:1); ¹H NMR (CDCl₃) δ 7.98 (d, 2 H, J = 7.2 Hz), 7.78 (s, 1 H), 7.51 (d, 1 H, J = 9.0 Hz), 7.43 (dd, 2 H, J = 7.2, 7.8 Hz), 7.32 (m, 1 H), 7.22 (dd, 1 H, J = 7.5, 9.0 Hz), 6.65 (d, 1 H, J = 7.5 Hz), 3.24 (s, 3 H), 3.09 (s, 3 H); ¹³C NMR (CDCl₃) δ 151.68, 147.18, 145.85, 140.66, 133.63, 128.60, 128.00, 126.19, 125.17, 113.80, 103.55, 101.97, 37.16, 36.78. Anal. Calcd for C₁₆H₁₅N₃O₂: C, 68.31; H, 5.37; N, 14.94. Found: C, 68.24; H, 5.40; N, 14.89.

General Procedure for Quaternization of Carbamates

A mixture of appropriate carbamate (1 equiv) and methyl *p*-toluenesulfonate or methyl iodide (1.5 equiv) in dry THF (or CH₃CN) was stirred at 60 °C overnight. Ether was added and the reaction mixture was cooled in ice. The precipitate was filtered and washed with several portions of ether to yield the product which was purified by recrystallization.

**1-Methyl-6-(N,N-dimethylcarbamoyloxy)imidazo[1,2-a]pyridinium
p-Toluenesulfonate (1) PN-III-268**

Following the general procedure for quaternization, the reaction of **1b** (0.103 g, 0.5 mmol) with methyl *p*-toluenesulfonate (0.14 g, 0.75 mmol) in dry THF (5 mL) gave **1** (0.19 g, 97 %) as a white solid: mp 176-177 °C; IR (KBr)_{vmax} 3138, 3045, 1732, 1184 cm⁻¹; ¹H NMR (CDCl₃) δ 9.05 (d, 1 H, J = 1.8 Hz), 8.65 (d, 1 H, J = 1.8 Hz), 8.13 (d, 1 H, J = 1.8 Hz), 7.99 (d, 1 H, J = 9.6 Hz), 7.79 (d, 2 H, J = 8.1 Hz), 7.66 (dd, 1 H, J = 1.8, 9.6 Hz), 7.13 (d, 2 H, J = 8.1 Hz), 4.12 (s, 3 H), 3.09 (s, 3 H), 3.01 (s, 3 H), 2.33 (s, 3 H); ¹³C NMR (CDCl₃) δ 153.23, 143.98, 143.22, 139.08, 136.96, 130.66, 128.55, 127.47, 125.81, 122.85, 116.10, 110.61, 36.94, 36.60, 34.60, 21.22. Anal. Calcd for C₁₈H₂₁N₃O₅S: C, 55.23; H, 5.41; N, 10.73. Found: C, 55.49; H, 5.40; N, 10.72.

**1,2-Dimethyl-6-(N,N-dimethylcarbamoyloxy)imidazo[1,2-a]pyridinium
p-Toluenesulfonate (2) PN-IV-33**

Following the general procedure for quaternization, the treatment of **2b** (55 mg, 0.25 mmol) with methyl *p*-toluenesulfonate (70 mg, 0.37 mmol) in dry THF (2 mL) gave **2** (95 mg, 94 %) as a white solid from MeOH/Et₂O: mp 223-224 °C; IR (KBr)_{vmax} 3113, 3049, 1716, 1184 cm⁻¹; ¹H NMR (DMSO-d₆) δ 8.97 (d, 1 H, J = 1.9 Hz), 8.18 (d, 1 H, J = 9.8 Hz), 8.15 (s, 1 H), 7.92 (dd, 1 H, J = 1.9, 9.8 Hz), 7.46 (d, 2 H, J = 7.9 Hz), 7.08 (d, 2 H, J = 7.9 Hz), 3.90 (s, 3 H), 3.08 (s, 3 H), 2.95 (s, 3 H), 2.49 (s, 3 H), 2.27 (s, 3 H); ¹³C NMR (DMSO-d₆) δ 152.93, 145.85, 142.44, 137.28, 137.10, 135.84, 129.37, 127.79, 125.32, 121.56, 112.42, 110.68, 36.43, 36.09, 30.79, 20.59, 9.22. Anal. Calcd for C₁₉H₂₃N₃O₅S: C, 56.28; H, 5.72; N, 10.36. Found: C, 56.37; H, 5.78; N, 10.36.

**1-Methyl-2-(2-propyl)-6-(N,N-dimethylcarbamoyloxy)imidazo[1,2-a]pyridinium
Iodide (3) PN-III-240**

Following the general procedure for quaternization, **3b** (1.27 g, 5.1 mmol) was reacted with an excess of methyl iodide in dry THF to give **3** (1.65 g, 82.5 %) as an off-white solid from CH₃CN/Et₂O: mp 180-181 °C; IR (KBr)_{vmax} 3068, 3032, 1734 cm⁻¹; ¹H NMR (CDCl₃) δ 9.10 (d, 1 H, J = 2.1 Hz), 8.58 (s, 1 H), 8.28 (d, 1 H, J = 9.9 Hz), 7.77 (dd, 1 H, J = 2.1, 9.9 Hz), 4.15 (s, 3 H), 3.28 (septet, 1 H, J = 6.9 Hz), 3.14 (s, 3 H), 3.02 (s, 3 H), 1.43 (d, 6 H, J = 6.9 Hz); ¹³C NMR (CDCl₃) δ 153.11, 145.49, 143.40, 137.49, 130.52, 121.77, 112.09, 111.40, 37.10, 36.84, 33.04, 24.96, 21.55. Anal. Calcd for C₁₄H₂₀IN₃O₂: C, 43.20; H, 5.18; N, 10.80. Found: C, 43.04; H, 5.23; N, 10.79.

1-Methyl-5-(N,N-dimethylcarbamoyloxy)imidazo[1,2-a]pyridinium Chloride (4)
PN-III-220

To a mixture of **4b** (1.0 g, 6.8 mmol) in dry THF (15 mL) and HMPT (2.35 mL, 13.5 mmol) was added slowly N,N-dimethylcarbamoyl chloride (1.24 mL, 13.5 mmol). The reaction mixture was stirred at 60 °C overnight, then cooled in an ice bath. Solvent was carefully removed by pipette and the solid was washed with ether and dried. Recrystallization of the crude in CH₃CN/ether gave **4** (1.38 g, 80 %) as a gray solid: mp 149-151 °C; ¹H NMR (CDCl₃) δ 8.90 (d, 1 H, J = 2.0 Hz), 8.12 (d, 1 H, J = 2.0 Hz), 8.07 (d, 1 H, J = 9.0 Hz), 8.00 (dd, 1 H, J = 7.7, 9.0 Hz), 7.32 (d, 1 H, J = 7.7 Hz), 4.42 (s, 3 H), 3.29 (s, 3 H), 3.12 (s, 3 H). Anal. Calcd for C₁₁H₁₄ClN₃O₂: C, 51.67; H, 5.52; Cl, 13.86; N, 16.43. Found: C, 51.43; H, 5.59; Cl, 13.73; N, 16.34.

1-Methyl-2-(2-propyl)-5-(N,N-dimethylcarbamoyloxy)imidazo[1,2-a]pyridinium Iodide (5) PN-IV-36

Following the general procedure for quaternization, **5b** (70 mg, 0.28 mmol) was treated with methyl iodide (excess) in THF (2 mL) to give **5** (99 mg, 96 %) as white needles from CH₃CN/Et₂O: mp 155-6 °C; IR (KBr)_{vmax} 3103, 3053, 1749, 1141 cm⁻¹; ¹H NMR (CDCl₃) δ 8.23 (d, 1 H, J = 9.0 Hz), 8.04 (dd, 1 H, J = 7.8, 9.0 Hz), 7.74 (s, 1 H), 7.32 (d, 1 H, J = 7.8 Hz), 4.21 (s, 3 H), 3.34 - 3.42 (m, 1 H), 3.33 (s, 3 H), 3.12 (s, 3 H), 1.48 (d, 6 H, J = 6.9 Hz); ¹³C NMR (CDCl₃) δ 150.06, 145.47, 141.95, 140.49, 134.92, 107.92, 107.57, 106.10, 37.57, 37.48, 33.33, 24.71, 21.40. Anal. Calcd for C₁₄H₂₀IN₃O₂·1/2 H₂O: C, 42.22; H, 5.32; N, 10.55. Found: C, 42.19; H, 5.36; N, 10.45.

**1-Methyl-2-phenyl-5-(N,N-dimethylcarbamoyloxy)imidazo[1,2-a]pyridinium Iodide
(6) PN-III-236**

Following the general procedure for quaternization, the reaction of **6b** (0.78 g, 2.8 mmol) with an excess of methyl iodide in dry THF (5 mL) gave **6** (0.92 g, 78.5 %) as white needles from (CH₃)₂CO/Et₂O: mp 156-157 °C; IR (KBr)_{vmax} 1755 cm⁻¹; ¹H NMR (CDCl₃) δ 8.16 (d, 1 H, J = 9.0 Hz), 8.04 (dd, 1 H, J = 8.0, 9.0 Hz), 7.96 (s, 1 H), 7.71-7.75 (m, 2 H), 7.57 - 7.62 (m, 3 H), 7.36 (dd, 1 H, J = 0.6, 8.0 Hz), 4.15 (s, 3 H), 3.29 (s, 3 H), 3.11 (s, 3 H); ¹³C NMR (CDCl₃) δ 150.22, 142.09, 140.90, 138.93, 135.35, 131.22, 130.29, 129.38, 124.28, 108.76, 108.16, 108.04, 37.58, 34.18. Anal. Calcd for: C₁₇H₁₈IN₃O₂: C, 48.24; H, 4.29; N, 9.93. Found: C, 48.08; H, 4.32; N, 9.93.

References

1. R. M. Black and G. S. Pearson, Chem. Britain, **29**, 584 (1993). L. R. Ember, Chem. Eng. News, April 18, 1994 pp. 16-19.
- 2) Anonymous, Chem. Eng. News, March 27, 1995, pp. 6-7.
- 3) P. Taylor, The Pharmacological Basis of Therapeutics, 7th edition, A. G. Gilman, L. S. Goodman, T. W. Rall and F. Murad editors, MacMillan, New York, 100-129 (1985).
- 4) E. Giacobini, Cellular and Molecular Basis of Cholinergic Function, M. J. Dowdall and T. N. Hawthorne, editors, Ellis Horwood, West Sussex UK, 882-901 (1987); G. P. Dawson, G. Bentley, F. Drapen, W. Rycroft, S. D. Iversen and P. G. Pagella, Pharmacol. Biochem. Behav., **39**, 865 (1991); L. L. Iversen, Prog. Brain Res., **98**, 423 (1993).
- 5) R. J. Sundberg, D. Dalvie, J. Cordero and H. A. Musallam, Chem. Res. Toxicol., **6**, 506 (1993).
- 6) Richard J. Sundberg and Phouc Van Nguyen, Annual Report DAMD-17-92-C-2081, July , 1993.
- 7) R. Graf, Chem. Ber., **64**, 21 (1931); J. G. Lombardino, J. Med. Chem., **24**, 39 (1981).
- 8) G. L. Ellman, K. D. Courtney, V. Andres and R. M. Featherstone, Biochem. Pharmacol., **2**, 88 (1961).
- 9) Prepared from 3-hydroxypyridine in 3 steps following the procedure described in Final Report, Contract Number DAMD-17-89-C-9017, 45 (1991).
- 10) M. Gaudry and Marquet A., Org. Synth. **55**, 24 (1976).
- 11) Seide, O. A. and Titow, A. I. Chem. Ber. **69** 1884 (1936).



DEPARTMENT OF THE ARMY

US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

21 Apr 97

MEMORANDUM FOR Administrator, Defense Technical Information
Center, ATTN: DTIC-OCF, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for Contract Number DAMD17-92-C-2081. Request the limited distribution statement for Accession Document Numbers ADB188021, ADB200784, ADB175882, and ADB211649 be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322.

FOR THE COMMANDER:


GARY R. GILBERT
Colonel, MS
Deputy Chief of Staff for
Information Management

*Completed
1-10-00
B.W*